Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for prevention of chemotherapy-induced nausea and vomiting
IRCT20210415050976N14Phase 2Completed
- Sponsor
- Jahrom University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Olanzapine plus standard antiemetic regimen with Placebo plus standard antiemetic regimen (2 arms). Primary endpoint: Complete response to treatment. Started Jan 2024; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20210415050976N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210415050976N14.